UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MALDI-TOF MS imaging of controlled release implants

Journal of controlled release, 2012-07, Vol.161 (1), p.98-108

2012

Volltextzugriff (PDF)

144 Evaluation of contamination and quantification of drug penetrations studies using Quantitative Mass Spectrometry Imaging

Journal of investigative dermatology, 2017-10, Vol.137 (10), p.S217-S217

2017

Volltextzugriff (PDF)

A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits

PloS one, 2012-11, Vol.7 (11), p.e50180

2012

Volltextzugriff (PDF)

128 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a potent novel peptide hair growth promoter, FOL-005

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.S22-S22

2018

Volltextzugriff (PDF)

1331 Glutathione (GSH) distribution by quantitative MALDI imaging in reconstructed human skin upon activation of GSH biosynthesis by Nrf2 pathway activator

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.S226-S226

2018

Volltextzugriff (PDF)

201 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a new potent novel inhibitor of human hair growth, FOL-005

Journal of investigative dermatology, 2016-09, Vol.136 (9), p.S195-S195

2016

Volltextzugriff (PDF)

695 Using MALDI-MSI analysis to study distribution of FOL-005, a potent, novel inhibitor of human hair growth, after subcutaneous injection in mice

Journal of investigative dermatology, 2016-05, Vol.136 (5), p.S123-S123

2016

Volltextzugriff (PDF)

106 Glutathione (GSH) distribution by quantitative MALDI imaging in reconstructed human skin upon activation of GSH biosynthesis by Nrf2 pathway activator

Journal of investigative dermatology, 2016-09, Vol.136 (9), p.S178-S178

2016

Volltextzugriff (PDF)

Quantitative and qualitative label free imaging using mass spectrometry in the context of an ophthalmic application

Acta ophthalmologica (Oxford, England), 2012-09, Vol.90 (s249), p.0-0

2012

Volltextzugriff (PDF)

167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial

Annals of oncology, 2022-05, Vol.33, p.S200-S200

2022

Volltextzugriff (PDF)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

BMJ open, 2022-03, Vol.12 (3), p.e055821-e055821

2022

Volltextzugriff (PDF)

Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study

Aging (Albany, NY.), 2015-12, Vol.7 (12), p.1066-1074

2015

Volltextzugriff (PDF)

190P French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients (pts) with HER2+ metastatic or unresectable breast cancer (m/u BC): First results of REALITY-01 ambispective study

ESMO open, 2024-05, Vol.9, p.103212, Article 103212

2024

Volltextzugriff (PDF)

Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts

Blood, 2002-08, Vol.100 (4), p.1113-1122

2002

Volltextzugriff (PDF)

Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): Results from the French randomized phase II study TORAVA

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15118-e15118

2011

Volltextzugriff (PDF)

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg m of melphalan in multiple myeloma: results of a pilot study including biological aspects

Bone marrow transplantation (Basingstoke), 2005-11, Vol.36 (9), p.771-779

2005

Volltextzugriff (PDF)

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4516-4516

2010

Volltextzugriff (PDF)

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma : results of a pilot study including biological aspects

Bone marrow transplantation (Basingstoke), 2005-11, Vol.36 (9), p.771-779

2005

Volltextzugriff (PDF)

Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6662-6662

2004

Volltextzugriff (PDF)

Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6662-6662

2004

Volltextzugriff (PDF)

Human anti‐mouse antibody response to the injection of murine monoclonal antibodies against IL‐6

Clinical and experimental immunology, 1994-11, Vol.98 (2), p.323-329

1994

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MALDI-TOF MS imaging of controlled release implants

144 Evaluation of contamination and quantification of drug penetrations studies using Quantitative Mass Spectrometry Imaging

A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits

128 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a potent novel peptide hair growth promoter, FOL-005

1331 Glutathione (GSH) distribution by quantitative MALDI imaging in reconstructed human skin upon activation of GSH biosynthesis by Nrf2 pathway activator

201 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a new potent novel inhibitor of human hair growth, FOL-005

695 Using MALDI-MSI analysis to study distribution of FOL-005, a potent, novel inhibitor of human hair growth, after subcutaneous injection in mice

106 Glutathione (GSH) distribution by quantitative MALDI imaging in reconstructed human skin upon activation of GSH biosynthesis by Nrf2 pathway activator

Quantitative and qualitative label free imaging using mass spectrometry in the context of an ophthalmic application

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS

167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study

Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. ICancers/I 2022, I14/I, 1510

Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14 , 1510

190P French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients (pts) with HER2+ metastatic or unresectable breast cancer (m/u BC): First results of REALITY-01 ambispective study

Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial

Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts

Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): Results from the French randomized phase II study TORAVA

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg m of melphalan in multiple myeloma: results of a pilot study including biological aspects

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma : results of a pilot study including biological aspects

Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS

Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS

Human anti‐mouse antibody response to the injection of murine monoclonal antibodies against IL‐6

Suchergebnisse filtern